Company: TACOW
Filing Date: 2025-04-15
Form Type: S-1/A
Source: 0001829126-25-002650
Chunk: 177

Company: Berto Acquisition Corp.
Filing Date: 2025-04-15
Form: S-1/A
Chunk 177
---
 462(b) under
the Securities Act, we will effect with our sponsor a share dividend or other appropriate mechanism, as applicable, with respect to our
ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by
our initial shareholders at 20% of our issued and outstanding ordinary shares upon the consummation of this offering. The issuance of
additional ordinary shares may further dilute the equity interests of public shareholders. Further, our sponsor or an affiliate of our
sponsor or certain of our officers and directors may loan us funds to finance transaction costs in connection with an intended initial
business combination. Such loans may be convertible into private placement warrants of the post-business combination entity at a price
of $1.00 per warrant at the option of the lender. The issuance of shares upon the exercise of such warrants may result in material dilution
to our public shareholders. See the sections titled “Dilution” and “Risk Factors — The nominal purchase price paid by our sponsor, sponsor affiliates and a consultant for the founder shares and the anti-dilution adjustment we intend to make with respect to the founder shares if the size of this offering is increased may result in significant dilution to the implied value of your public shares upon the consummation of our initial business combination, and the value of the founder shares following completion of our initial business combination is likely to be substantially higher than the nominal price paid for them, even if the trading price of our ordinary shares at such time is substantially less than $10.00 per share.”

Our founder shares are of the
same class as the ordinary shares included in the units being sold in this offering. Our founder shares are identical to the public shares
except that the founder shares are entitled to registration rights and subject to certain transfer restrictions, as described in more
detail in this prospectus. Unlike in other SPACs, our founder shares do not have conversion and anti-dilution rights in connection with
the closing of a business combination. Therefore, if additional ordinary shares or equity-linked securities are issued or deemed issued
in connection with our initial business combination, our founder shares will be diluted by such issuance pro rata with the public shares.

Pursuant to a letter agreement
to be entered with us, each of our sponsor, officers and directors, and the consultant who owns founder shares has agreed to restrictions
on its ability to transfer, assign, or sell the founder shares and private placement warrants, as summarized in the